Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.09.010 ◽

2021 ◽

Author(s):

R.J. Edmondson ◽

R.L. O'Connell ◽

S. Banerjee ◽

L. Mileshkin ◽

P. Sykes ◽

...

Keyword(s):

Estrogen Receptor ◽

Progesterone Receptor ◽

Phase 2 ◽

Uterine Corpus ◽

Download Full-text

PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5524 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5524-5524 ◽

Author(s):

Susana N. Banerjee ◽

Monica Tang ◽

Rachel O'Connell ◽

Andrew R. Clamp ◽

Rosemary Lord ◽

...

Keyword(s):

Estrogen Receptor ◽

Progesterone Receptor ◽

Granulosa Cell ◽

Phase 2 ◽

Stromal Tumors ◽

Granulosa Cell Tumors ◽

Phase 2 Study ◽

Positive Recurrent ◽

Sex Cord Stromal Tumors

Download Full-text

Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.02.016 ◽

2021 ◽

Author(s):

M. Friedlander ◽

C. Benson ◽

R.L. O'Connell ◽

N. Reed ◽

A. Clamp ◽

...

Keyword(s):

Estrogen Receptor ◽

Progesterone Receptor ◽

Low Grade ◽

Phase 2 ◽

Phase 2 Study ◽

Positive Recurrent

Download Full-text

OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-16 ◽

2011 ◽

Author(s):

BD Lu ◽

JL Blum ◽

J Cortes ◽

HS Rugo ◽

C Swanton ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive

Download Full-text

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Randomized Phase 2

Download Full-text

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

10.1158/0008-5472.sabcs13-p2-16-04 ◽

2013 ◽

Author(s):

J Baselga ◽

SM Morales ◽

A Awada ◽

JL Blum ◽

AR Tan ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive

Download Full-text

A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.07.024 ◽

2021 ◽

Author(s):

Susana N. Banerjee ◽

Monica Tang ◽

Rachel L. O'Connell ◽

Katrin Sjoquist ◽

Andrew R. Clamp ◽

...

Keyword(s):

Progesterone Receptor ◽

Granulosa Cell ◽

Oestrogen Receptor ◽

Phase 2 ◽

Phase 2 Study ◽

Granulosa Cell Tumours ◽

Positive Recurrent

Download Full-text

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1005 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1005-1005 ◽

Author(s):

Guy Heinrich Maria Jerusalem ◽

Elena Kovalenko ◽

Denise A. Yardley ◽

Richard H. De Boer ◽

Sara A. Hurvitz ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Open Label Phase ◽

Epidermal Growth

Download Full-text

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2016.03.005 ◽

2016 ◽

Vol 16 (4) ◽

pp. 256-261 ◽

Author(s):

Kari B. Wisinski ◽

Wei Xu ◽

Amye J. Tevaarwerk ◽

Sandeep Saha ◽

KyungMann Kim ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Estrogen Receptor Beta ◽

High Dose ◽

Phase 2 ◽

Phase 2 Study ◽

Download Full-text

Abstract OT2-1-02: A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer

10.1158/1538-7445.sabcs14-ot2-1-02 ◽

2015 ◽

Author(s):

Andre Mattar ◽

Rodrigo Goncalves ◽

Matthew J Ellis ◽

Roberto Hegg

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Premenopausal Women ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive

Download Full-text

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e86 ◽

2019 ◽

Vol 30 (5) ◽

Author(s):

Peey-Sei Kok ◽

Philip Beale ◽

Rachel L. O'Connell ◽

Peter Grant ◽

Tony Bonaventura ◽

...

Keyword(s):

Ovarian Cancer ◽

Progesterone Receptor ◽

Recurrent Ovarian Cancer ◽

Phase 2 ◽

Asymptomatic Patients ◽

Phase 2 Study ◽

Positive Recurrent ◽

Estrogen And Progesterone Receptor

Download Full-text